CDX2 Antibody

Product Specs
ItemCDX2 Antibody - BSA Free
CompanyNovus Biologicals, a Bio-Techne Brand
Price $479.00Supplier Page View Company Product Page
Catalog NumberNB100-2136
ImmunogenThe immunogen recognized by this antibody maps to a region between residue 250 and 300 of human Caudal Type Homeobox Transcription Factor 2 using the numbering given in entry NP_001256.1 (GeneID 1045)
NCBI Gene AliasesCDX2/AS, CDX3, CDX-3
Concentration1.0 mg/ml
Conjugate/TagUnconjugated
FormatTris-Citrate/Phosphate (pH 7.0 - 8.0)
HostRabbit
Quantity100 ul
TargetCDX2
ApplicationsIF/IHC,Immunohistochemistry,Immunoprecipitation,Immunohistochemistry-Paraffin, Microarray,Immunocytochemistry/ Immunofluorescence
ReactivityHuman,Mouse
IsotypeIgG
NCBI Full Gene Namecaudal type homeobox 2
ClonalityPolyclonal
PurityImmunogen affinity purified
Antibody TypePrimary Antibodies
Research AreaCancer, Chromatin Research, DNA Repair, Growth and Development, Transcription Factors and Regulators
StorageStore at 4C. Do not freeze

Specifications/Features

Available conjugates: Available conjugates: Unconjugated

Sizes Available: 100 ul

Questions and Answers

Can this antibody be used for immunohistochemistry in colorectal cancer research?

Yes, the CDX2 antibody has been utilized in immunohistochemistry for assessing consensus molecular subtype status in stage II colorectal cancer, as demonstrated in a study where it was used at a dilution of 1:200 to evaluate its prognostic value for adjuvant chemotherapy efficacy ().

What species does this antibody react with, and is it suitable for human studies?

The CDX2 antibody is reactive with both human (Homo sapiens) and mouse species, making it suitable for studies involving these organisms.

Is there any evidence supporting the use of this antibody in cancer research?

The CDX2 antibody has been cited in multiple scientific articles, including a study that highlights its role in determining consensus molecular subtype status, which is a prognostic biomarker for adjuvant chemotherapy in stage II colorectal cancer ().

What is the immunogen for this antibody, and how does it relate to its specificity?

The immunogen recognized by the CDX2 antibody maps to a region between residues 250 and 300 of the human Caudal Type Homeobox Transcription Factor 2. This specificity is crucial for its application in accurately identifying CDX2 expression in various tissues, particularly in cancer research contexts.

Novus Biologicals, a Bio-Techne Brand

United States: 10771 E Easter Ave

Centennial, Colorado 80112

United States

Phone:
303-730-1950
888-506-6887

Email: novus@novusbio.com

Company Profile

Website: https://www.novusbio.com

(1) Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responsesFrontiers in immunologyJanuary 1, 2026Wang X, Liu L, Li F, Da Y, Hu F, Qi X, Pan Y, Jiang M, Hou P, Yang J.abcam), anti-CK7 (1:400, GB12225, Servicebio), anti-CK20 (1:100, ab76126, abcam), and anti-CDX2 (1:800, NB100-2136, Novus). Next-generation sequencing—425-gene panel DNA panel sequencing was conducted by Geneseeq

(2) Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal CancerCell stem cellJanuary 2, 2020Yao Y, Xu X, Yang L, Zhu J, Wan J, Shen L, Xia F, Fu G, Deng Y, Pan M, et al.

(3) Transcriptional networks driving enhancer function in the CFTR geneThe Biochemical journalJanuary 1, 0001"Kerschner JL, Harris A."

(4) "TCF4 and CDX2, major transcription factors for intestinal function, converge on the same cis-regulatory regions"Proceedings of the National Academy of Sciences of the United States of AmericaJanuary 1, 0001"Verzi MP, Hatzis P, Sulahian R, Philips J, Schuijers J, Shin H, Freed E, Lynch JP, Dang DT, Brown M, et al."

(5) Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by ImmunohistochemistryClinical cancer research : an official journal of the American Association for Cancer ResearchJanuary 1, 0001"Trinh A, Trumpi K, De Sousa E Melo F, Wang X, de Jong JH, Fessler E, Kuppen PJ, Reimers MS, Swets M, Koopman M, et al."

(6) Depletion of oocyte dynamin-related protein 1 shows maternal-effect abnormalities in embryonic developmentScience advancesJanuary 1, 0001"Adhikari D, Lee IW, Al-Zubaidi U, Liu J, Zhang QH, Yuen WS, He L, Winstanley Y, Sesaki H, Mann JR, et al."H3K27me3 (Merck Millipore no. 07-449), H3K4me3 (Active Motif no. 39159), CDX2 (Novus Biologicals no. NB100-2136), OCT-4 (Abcam no. ab184665), H3K9me3 (Cell Signaling Technology no. 13969), TOM20 (Santa Cruz Biotechnology

(7) Stromal SOX2 Upregulation Promotes Tumorigenesis through the Generation of a SFRP1/2-Expressing Cancer-Associated Fibroblast PopulationDevelopmental cellJanuary 1, 0001"Kasashima H, Duran A, Martinez-Ordoñez A, Nakanishi Y, Kinoshita H, Linares JF, Reina-Campos M, Kudo Y, L'Hermitte A, Yashiro M, et al."Sigma HPA012867), rabbit anti-FRMD6 (1:100, Abcam ab218209), rabbit anti-CDX2 (1:200, Novus Biologicals NB100-2136), rabbit anti-ZEB1 (1:500, Sigma HPA027524), mouse anti-Cytokeratin Pan Type I/II (1:500, Invitrogen

(8) Metabolic shift underlies tumor progression and immune evasion in S-nitrosoglutathione reductase-deficient cancerThe Journal of pathologyJanuary 1, 0001"Mena-Osuna R, Mantrana A, Guil-Luna S, Sánchez-Montero MT, Navarrete-Sirvent C, Morales-Ruiz T, Rivas-Crespo A, Toledano-Fonseca M, García-Ortíz MV, García-Jurado G, et al."

(9) Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancerPloS oneJanuary 1, 0001"Mochizuki K, Kudo SE, Kato K, Kudo K, Ogawa Y, Kouyama Y, Takashina Y, Ichimasa K, Tobo T, Toshima T, et al."refrigerator at 4°C overnight; the primary antibodies used were anti-CDX2 (1:200; Novus Biologicals; NB100-2136), anti-HTR2B (1:75; Sigma-Aldrich; HPA012867), anti-FRMD6 (1:500; Sigma-Aldrich; HPA001297), anti-ZEB1

(10) Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short reportCellular oncology (Dordrecht)January 1, 0001"Sandberg TP, Sweere I, van Pelt GW, Putter H, Vermeulen L, Kuppen PJ, Tollenaar RAEM, Mesker WE."goat serum (Sigma). Sections were incubated overnight with an anti-CDX2 antibody (Novus Biologicals, NB100–2136, 1:200). On the following day, the sections were incubated for 30 min with a HRP-labelled anti-rabbit

(11) Essential and redundant functions of caudal family proteins in activating adult intestinal genesMolecular and cellular biologyJanuary 1, 0001"Verzi MP, Shin H, Ho LL, Liu XS, Shivdasani RA."

(12) Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal CancerThe oncologistJanuary 1, 0001"Li Y, Yao Q, Zhang L, Mo S, Cai S, Huang D, Peng J."HPA012867; Sigma‐Aldrich, St. Louis, MO), anti‐FRMD6 (1:500; HPA001297; Sigma‐Aldrich), anti‐CDX2 (1:200; NB100‐2136; Novus Biologicals, Centennial, CO), anti‐ZEB1 (1:500; HPA027524; Sigma‐Aldrich), or anticytokeratin

(13) Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesionsNature medicineJanuary 1, 0001"De Sousa E Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, de Jong JH, de Boer OJ, van Leersum R, Bijlsma MF, et al."

Be the First to Write a Review!

CDX2 Antibody

CDX2 Antibody

CDX2 Antibody - BSA Free from Novus Biologicals, a Bio-Techne Brand

Specifications/Features

Questions and Answers

Novus Biologicals, a Bio-Techne Brand

Citations (13)

Reviews

CDX2 Antibody - BSA Free from Novus Biologicals, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map